why choose us

First received: June 02, 2023

Clinical Trial: Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Peripheral T Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Brief Summary: This is a non-randomized, open-label, Phase 1b clinical study to evaluate the safety, tolerability and anti-tumor efficacy of SHR0302 as monotherapy in patients with relapsed/refractory peripheral T/NK cell lymphoma.Around 7-18 patients will be subsequently enrolled into 3 different dose ascending cohorts.Additional 12-18 patients may be enrolled to further explore a selected dose defined by dose escalation cohorts.

Read more